Viewing Study NCT01882361


Ignite Creation Date: 2025-12-24 @ 11:53 AM
Ignite Modification Date: 2026-01-02 @ 2:16 PM
Study NCT ID: NCT01882361
Status: COMPLETED
Last Update Posted: 2020-11-06
First Post: 2013-06-14
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone
Sponsor: University of Pennsylvania
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Opiate Dependence View
None Human Immunodeficiency Virus View
Keywords:

Keywords

Keyword Brief Keyword Text View
None opioid addiction View
None opioid treatment View
None naloxone View